Novel renoprotective actions of erythropoietin: New uses for an old hormone

Nephrology

Volumn 11, Issue 4, 2006, Pages 306-312

  Johnson, David W ^a,b   Forman, Colin ^a   Vesey, David A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Apoptosis; Darbepoetin; Erythropoietin; Kidney failure; Renoprotection; Signalling pathway

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ACUTE KIDNEY FAILURE; CELL PROTECTION; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HYPOXIA; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW;

ERYTHROPOIETIN; HUMANS; KIDNEY FAILURE; RENAL INSUFFICIENCY;

EID: 33746174151     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00585.x     Document Type: Review

References (46)

1. Carnot P, Deflandre C. Haemopoietic activity of the serum in blood regeneration. C. R. Acad. Sci. (Paris) 1906; 143: 384-6.
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977; 252: 5558-64.
3. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 1985; 82: 7580-84.
4. Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-10.
5. Li F, Chong ZZ, Maiese K. Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004; 13: 265-89.
6. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol. Rev. 1992; 72: 449-89.
7. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999; 55: 808-20.
8. Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: What's new? Fundam. Clin. Pharmacol. 2005; 19: 439-46.
9. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-7.
10. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am. J. Physiol. Endocrinol. Metab. 2000; 279: E1242-8.
11. Bahlmann FH, de Groot K, Haller H, Fliser D. Erythropoietin: Is it more than correcting anaemia? Nephrol. Dial. Transplant. 2004; 19: 20-22.
12. Sinor AD, Greenberg DA. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci. Lett. 2000; 290: 213-15.
13. Ruscher K, Freyer D, Karsch M et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J. Neurosci. 2002; 22: 10291-301.
14. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA 1998; 95: 4635-40.
15. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA 2000; 97: 10526-31.
16. Grasso G, Buemi M, Alafaci C et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc. Natl. Acad. Sci. USA 2002; 99: 5627-31.
17. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 2002; 8: 495-505.
18. Abdelrahman M, Sharples EJ, McDonald MC et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63-9.
19. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J. Histochem. Cytochem. 1993; 41: 335-41.
20. Gong H, Wang W, Kwon TH et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004; 66: 683-95.
21. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant. 2004; 19: 348-55.
22. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischaemic acute renal injury and failure. Kidney Int. 2006; 69: 1806-13.
23. Bagnis C, Beaufils H, Jacquiaud C et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol. Dial. Transplant. 2001; 16: 932-8.
24. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am. J. Physiol. 1994; 266: F360-66.
25. Patel NS, Sharples EJ, Cuzzocrea S et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004; 66: 983-9.
26. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001; 59: 246-51.
27. Fishbane S, Ragolia L, Palaia T, Johnson B, Elzein H, Maesaka JK. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int. 2004; 65: 452-8.
28. Baldwin MD, Zhou XJ, Ing TS, Vaziri ND. Erythropoietin ameliorates anemia of cisplatin induced acute renal failure. ASAIO J. 1998; 44: 44-7.
29. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 2004; 15: 2115-24.
30. Yang CW, Li C, Jung JY et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003; 17: 1754-5.
31. Ates E, Yalcin AU, Yilmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J. Surg. 2005; 75: 1100-105.
32. Spandou E, Tsouchnikas I, Karkavelas G et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol. Dial. Transplant. 2006; 21: 330-36.
33. Bahlmarm FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-12.
34. Kang DH, Park EY, Yu ES, Lee YS, Yoon KI. Renoprotective effect of erythropoietin (EPO): Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int. 2005; 67: 1683.
35. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol. Dial. Transplant. 2003; 18: 543-51.
36. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
37. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in preanalysis patients. Nephrol. Dial. Transplant. 2001; 16: 307-12.
38. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004; 66: 753-60.
39. Harris DCH, Thomas M, Johnson DW, Nicholls K, Gillin A. Prevention of progression of kidney disease. Nephrology 2006; 11 (Suppl. 1): S2-S197.
40. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
41. Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. USA 2003; 100: 6741-6.
42. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int. 1993; 44: 430-35.
43. Kusano E, Akimoto T, Inoue M et al. Human recombinant erythropoietin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. Nephrol. Dial. Transplant. 1999; 14: 597-603.
44. Figueroa YG, Chan AK, Ibrahim R et al. NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp. Hematol. 2002; 30: 1419-27.
45. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004; 9 (Suppl. 5): 18-30.
46. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000; 58: 647-57.